New Peptide ETF From REX Looks Beyond GLP-1 Drugs
REX launched a peptide ETF that tracks 36 peptide-linked companies, including GLP-1 drugmakers as well as device and supplement makers.
Why it matters — The launch is a new fund offering from REX and broadens its focus beyond GLP-1 drugmakers to companies across the peptide ecosystem.